Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MT-3921 in acute traumatic cervical spinal cord injury
jRCT2031210320Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in acute cervical spinal cord injury (ACSCI) comparing MT-3921 with Placebo (2 arms). Primary endpoint: Change from baseline at Day 180 in Upper Extremity Motor Score. Started Mar 2022; status: completed.
02
Drugs
unasnemab
03
Conditions
acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on jRCT2031210320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210320.